Paper17538160
Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.
Temam S and 9 others. J Clin Oncol, 2007. Cited by 309 papers, by iCite.
Cite this record
ConductScience Library. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. Papers, record 17538160. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17538160
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Squamous Cell | Major topic |
| ErbB Receptors | Major topic |
| Gene Dosage | Major topic |
| Head and Neck Neoplasms | Major topic |
| Mutation | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Female | |
| Humans | |
| Immunohistochemistry | |
| In Situ Hybridization, Fluorescence | |
| Male | |
| Middle Aged |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA106451 | NCI NIH HHS | United States | P01CA106451 | PubMed and NIH | NIH RePORTER |
| CA16672 | NCI NIH HHS | United States | P01CA016672 | PubMed and NIH | NIH RePORTER |
| P30CA016672 | NIH | NIH RePORTER |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 17538157 | Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions. | https://conductscience.org/library/papers/17538157 |
Source PubMed
Cited by162
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 309 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41474664 | Phytochemicals as Emerging Antiproliferative Agents in Head and Neck Cancer: Molecular Mechanisms and Therapeutic Strategies. | Pharmacology | 2026 | https://conductscience.org/library/papers/41474664 | PubMed |
| 41044775 | Interferon signaling and STING pathway in head and neck cancers: unlocking immune secrets and therapeutic frontiers. | Cancer Cell Int | 2025 | https://conductscience.org/library/papers/41044775 | PubMed |
| 40364160 | EGFR-Mutant Urothelial Carcinoma Harboring an Ala750_Ile759delinsGlyGly Alteration with a Primary Resistance to Polychemotherapy and a Sensitivity to Osimertinib: A Literature Review on EGFR Alterations and Response to EGFR Tyrosine Kinase Inhibitors in Cancers. | J Clin Med | 2025 | https://conductscience.org/library/papers/40364160 | PubMed |
| 40301868 | Salivary EGF: EGFR ratio as potential early diagnostic biomarker for oral cancer detection in tobacco chewers: a preliminary cross-sectional study. | BMC Oral Health | 2025 | https://conductscience.org/library/papers/40301868 | PubMed |
| 39900969 | Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck. | Nat Rev Clin Oncol | 2025 | https://conductscience.org/library/papers/39900969 | PubMed |
| 39043526 | Blocking β2-AR and Inhibiting COX-2: A Promising Approach to Suppress OSCC Development. | Int Dent J | 2025 | https://conductscience.org/library/papers/39043526 | PubMed |
| 38920648 | Overcoming Resistance to Standard-of-Care Therapies for Head and Neck Squamous Cell Carcinomas. | Cells | 2024 | https://conductscience.org/library/papers/38920648 | PubMed |
| 38873325 | Anti‑epidermal growth factor receptor monoclonal antibody therapy in locally advanced head and neck cancer: A systematic review of phase III clinical trials. | Med Int (Lond) | 2024 | https://conductscience.org/library/papers/38873325 | PubMed |
| 38536540 | Palbociclib inhibits the progression of head and neck cancer and improves the Cetuximab response under specific condition in vitro and in vivo. | Mol Biol Rep | 2024 | https://conductscience.org/library/papers/38536540 | PubMed |
| 38398017 | Current and Emerging Diagnostic, Prognostic, and Predictive Biomarkers in Head and Neck Cancer. | Biomedicines | 2024 | https://conductscience.org/library/papers/38398017 | PubMed |
| 37898690 | Recombinant immunotoxin induces tumor intrinsic STING signaling against head and neck squamous cell carcinoma. | Sci Rep | 2023 | https://conductscience.org/library/papers/37898690 | PubMed |
| 37559138 | Circulating tumour DNA alterations: emerging biomarker in head and neck squamous cell carcinoma. | J Biomed Sci | 2023 | https://conductscience.org/library/papers/37559138 | PubMed |
| 36835812 | Effect of Opioid Receptor Activation and Blockage on the Progression and Response to Treatment of Head and Neck Squamous Cell Carcinoma. | J Clin Med | 2023 | https://conductscience.org/library/papers/36835812 | PubMed |
| 36612264 | Novel Strategies for the Bioavailability Augmentation and Efficacy Improvement of Natural Products in Oral Cancer. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36612264 | PubMed |
| 36454443 | Molecular pathways modulated by phytochemicals in head and neck cancer. | J Cell Commun Signal | 2023 | https://conductscience.org/library/papers/36454443 | PubMed |
| 36262474 | Comprehensive landscape of the functions and prognostic value of RNA binding proteins in uterine corpus endometrial carcinoma. | Front Mol Biosci | 2022 | https://conductscience.org/library/papers/36262474 | PubMed |
| 36114912 | Benzimidazole-linked pyrazolo[1,5-a]pyrimidine conjugates: synthesis and detail evaluation as potential anticancer agents. | Mol Divers | 2023 | https://conductscience.org/library/papers/36114912 | PubMed |
| 36092724 | Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma. | Front Cell Dev Biol | 2022 | https://conductscience.org/library/papers/36092724 | PubMed |
| 36010285 | Identification of EGFR as a Biomarker in Saliva and Buccal Cells from Oral Submucous Fibrosis Patients-A Baseline Study. | Diagnostics (Basel) | 2022 | https://conductscience.org/library/papers/36010285 | PubMed |
| 35975731 | The association between body mass index and efficacy of pembrolizumab as second-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma. | Cancer Med | 2023 | https://conductscience.org/library/papers/35975731 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17538160
GET https://conductscience.org/api/papers/v1/17538160/cited_by?page=2